| Studies | OS/ differences of median | HR/p |
|---|---|---|
| FOLFIRINOX vs. gemcitabine | 11.1 months - 6.8 months 4.3 months | HR 0.57 (95% CI 0.45–0.73) P < 0.001 |
| Nab-paclitaxel/ gemcitabine vs. gemcitabine | 8.5 months - 6.7 months 1.8 months | HR = 0.72 (95% CI0.617–0.835) P < 0.001 |
| erlotinib/ gemcitabine vs. placebo/gemcitabine | 6.2 months - 5.9 months 0.33 months | HR = 0.82 (95% CI0.69 to 0.99) P = 0.038 |
| Indirect Comparison (Bucher’s Method, ITC calculator) | ||
| Equivalence interval (0.75 to 1.33) | ||
| OS | HR (CI95%) | p |
| Overall Survival FOLFIRINOX vs. Nab-paclitaxel/gemcitabine | HR = 0.79 (95% CI 0.6 to 1.05) | p > 0.05 |
| Overall Survival Nab-paclitaxel/gemcitabine vs. erlotinib/gemcitabine | HR = 0.88 (95% CI 0.74 to 1.04) | p > 0.05 |
| Overall Survival FOLFIRINOX vs. erlotinib/gemcitabine | HR = 0.70 (95% CI 0.69 to 0.49) | p = 0.04 |
| Adverse event | Risk difference (95% CI) | p |
| Grade 3/4 neutropenia FOLFIRINOX vs. Nab-paclitaxel/gemcitabine | 2.23% (1.03 to 4.83) | p = 0.04 |
| Grade 3/4 neutropenia Nab-paclitaxel/gemcitabine vs. erlotinib/gemcitabine | 0.80% (0.36 to 1.78) | p = 0.59 |
| Grade 3/4 neutropenia FOLFIRINOX vs. erlotinib/gemcitabine | 1.76% (0.94 to 3.31) | p = 0.08 |